For
immediate release
|
01 August
2024
|
ANGLE plc ("the Company")
INDEPENDENT PARSORTIX STUDY
HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA
Multi-analyte approach has potential
to guide personalised cancer care
CTC mutation profiles associated
with more aggressive disease
ANGLE plc (AIM:AGL OTCQX:ANPCY), a
world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development
and clinical oncology, is pleased to announce the
results of an independent study in melanoma
patients comparing gene mutations in tumour tissue, circulating
tumour DNA (ctDNA) and CTCs.
The study, from Dr Laura Keller's
team at the Department of Tumor Biology, University Medical Center
Hamburg-Eppendorf, Germany, used the Parsortix® system
to isolate CTCs from melanoma patient blood samples. The CTCs were
analysed alongside tumour tissue and ctDNA samples using PCR (for
gene amplification) followed by mass spectrometry.
The study found a significantly
wider range of potentially clinically relevant DNA mutations in the
CTCs (intact cancer cells harvested by the Parsortix system)
compared to the ctDNA samples (DNA fragments released from dead and
dying tumour cells). Mutations were identified in CTCs but
not in matched ctDNA samples which are clinically relevant when
detected in tumour tissue, with US Food and Drug Administration
approved targeted drugs available.
Analysis of two specific mutations
which are commonly screened for in a clinical setting for melanoma
(BRAF and NRAS) identified notable differences
in the CTC samples compared to the tissue samples. The mutations
identified in CTCs but not in matched tissue samples were
associated with a more aggressive phenotype of the disease and may
reflect clonal evolution of the cancer during the time elapsed
between tissue biopsy and CTC blood sample (median elapsed time 6
months; range 0 to 41 months).
The authors state that the genomic
analysis of CTCs has the potential to provide additional and
complementary information on clinically relevant mutations compared
to those found in tumour tissue and/or ctDNA. The authors conclude
that the integration of a multi-analyte approach has the potential
to further the evolution of personalised medicine in the field of
cancer care.
ANGLE Chief Scientific Officer,
Karen Miller commented:
"We are
pleased to share this peer-reviewed publication by the University
Medical Center in Hamburg-Eppendorf,
Germany. The paper demonstrates the potential utility of CTCs
enriched using the Parsortix system to provide genomic information
additional to that provided by tumour tissue or ctDNA analysis. It
highlights how mutational analysis of CTCs, isolated using the
Parsortix system, from patients with melanoma could, in the future,
enable clinicians to make more informed decisions regarding their
patient's treatment and care pathway."
For
further information:
ANGLE plc
|
+44
(0) 1483 343434
|
Andrew Newland, Chief
Executive
Ian Griffiths, Finance
Director
|
|
Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo
Bonser
|
+44
(0) 20 3207 7800
|
FTI
Consulting
Simon Conway, Ciara
Martin
Matthew Ventimiglia (US)
|
+44
(0) 203 727 1000
+1
(212) 850 5624
|
For Research Use Only. Not for use
in diagnostic procedures.
For Frequently Used Terms, please
see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid
biopsy company with innovative circulating tumour cell (CTC)
solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting
technology known as the Parsortix® PC1 system enables
complete downstream analysis of the sample including whole cell
imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.
ANGLE's commercial businesses are
focusing on diagnostic products and clinical services. Diagnostic
products include the Parsortix® system and associated
consumables. The clinical services business is offered through
ANGLE's GCP-compliant laboratories in the UK. Services
include custom made assay development and clinical trial testing
for pharma.
Over 90 peer-reviewed publications
have demonstrated the performance of the Parsortix system. For more
information, visit www.angleplc.com